Physician

Pavan K Yerramsetty, M.D.

According to 2025 Medicare claims, Pavan Yerramsetty, M.D. (NPI: 1245269513) practices neurology in the Raleigh-Cary, NC market, with the plurality of this provider's patient population coming from Wake, NC. This provider's primary affiliated billing organization is RALEIGH NEUROLOGY ASSOCIATES, P. A. (NPI: 1215954003; TIN: 562002729) and primary practice location at 27607-5253.

Yerramsetty's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 591 traditional Medicare patients, billed 64,037 HCPCS/CPT codes, and received $1,035,357 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 3,765 prescription claims across 694 beneficiaries totaling $269,717 in drug costs, led by Buprenorphine (Buprenorphine). 2017 DME data shows 12 claims. Open Payments data shows 112 records totaling $2,244. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $191,612 to $1,035,357. In contrast, Part D prescription costs have declined steadily, from $499,444 to $269,717. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	683	4,438	$191,612
2016	699	8,840	$254,201
2017	699	21,458	$430,233
2018	707	20,159	$458,565
2019	658	21,435	$507,758
2020	550	25,872	$607,250
2021	535	11,921	$240,279
2022	558	11,764	$380,890
2023	529	35,437	$1,008,818
2024	591	64,037	$1,035,357

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	522	3,628	$499,444
2016	477	3,181	$407,380
2017	534	2,748	$402,311
2018	543	2,633	$500,343
2019	519	2,271	$373,048
2020	540	2,800	$457,577
2021	573	3,012	$331,554
2022	588	2,774	$237,266
2023	613	3,269	$288,802
2024	694	3,765	$269,717

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	12	$817
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	75	75	$125
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	161	161	$107
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	176	233	$84
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	113	128	$12
J0702	Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg	169	738	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Buprenorphine	Buprenorphine	140	3,928	$28,743
Ajovy Autoinjector	Fremanezumab-Vfrm	26	852	$22,596
Lamictal	Lamotrigine	13	390	$18,012
Aimovig Autoinjector	Erenumab-Aooe	21	630	$15,642
Ubrelvy	Ubrogepant	15	450	$15,089

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	111	$2,244	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	1	$25,000	Contego Medical, Inc

Explore More Providers

FAQ

What Medicare data is available for Pavan K. Yerramsetty, M.D.?

Tedicare shows public-source Medicare data for Pavan K. Yerramsetty, M.D. (NPI 1245269513), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Pavan K. Yerramsetty, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Pavan K. Yerramsetty, M.D.?

Pavan K. Yerramsetty, M.D. is linked to RALEIGH NEUROLOGY ASSOCIATES, P. A. (billing NPI 1215954003) in the available physician profile data.

Does Pavan K. Yerramsetty, M.D. have Open Payments data?

Pavan K. Yerramsetty, M.D. has 112 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.